In today’s briefing:
- IKang Healthcare (KANG US): Another Setback For Dissenters
- Ohayo Japan | Inflation Hits Stocks; Shimano Hits a Pothole
- Shroom Shmooz – Spotlight on MDMA
IKang Healthcare (KANG US): Another Setback For Dissenters
- In officially decided cases concerning dissentient shareholders in privatised US-listed China plays, the uplift to the merger price versus time value of money and legal costs, is less than ideal.
- The outcome for each case will turn on the underlying facts. But it would appear iKang Healthcare Group (ADR) (KANG US) is following a similar trend.
- Reportedly the uplift to the iKang merger price is just 10%. Dissenters can still lodge an appeal.
Ohayo Japan | Inflation Hits Stocks; Shimano Hits a Pothole
- Dow loses over 500 points, its biggest daily loss in over 10 months, as Treasury yields surged 14bps to 4.3%
- Shimano announces disappointing 2024 earnings guidance, well short of street estimates. Perhaps time to do more on capital allocation
- Sapporo looks like it is bowing to pressure from activist, 3D Partners, regarding a potential sale of non-core real estate
Shroom Shmooz – Spotlight on MDMA
- In the second of our series of spotlights on psychedelic therapies, we look at 3,4-methylenedioxymethamphetamine (MDMA), a Schedule I substance that is leading the psychedelic charge to therapeutic legitimacy.
- MDMA, better known as ecstasy or molly, is a pure human- made synthesized compound that uniquely combines the characteristics of a stimulant with hallucinogenic properties.
- No other psychedelic shares those characteristics. The parallel release of dopamine and serotonin brings together a positive mood and prosocial effects.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
